Carcinoma, Hepatocellular
Showing NaN - NaN of 19
Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)
Recruiting
- Carcinoma, Hepatocellular
- Relatlimab
- +3 more
-
Los Angeles, California
- +62 more
Feb 1, 2023
Carcinoma, Hepatocellular Trial in Worldwide (drug, biological, procedure)
Active, not recruiting
- Carcinoma, Hepatocellular
- Lenvatinib
- +4 more
-
Tucson, Arizona
- +206 more
Jan 31, 2023
Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer Trial in Worldwide (RO7119929, Tocilizumab)
Completed
- Carcinoma, Hepatocellular
- +3 more
-
Duarte, California
- +9 more
Jan 27, 2023
Carcinoma, Hepatocellular Trial in Spain (Atezolizumab, Bevacizumab)
Active, not recruiting
- Carcinoma, Hepatocellular
-
Elche, Alicante, Spain
- +26 more
Dec 5, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)
Active, not recruiting
- Carcinoma, Hepatocellular
-
Los Angeles, California
- +138 more
Aug 22, 2022
Carcinoma, Hepatocellular, Colorectal Tumors, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Pembrolizumab, Belzutifan,
Recruiting
- Carcinoma, Hepatocellular
- +5 more
- Pembrolizumab
- +2 more
-
Duarte, California
- +39 more
Jul 29, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)
Active, not recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +2 more
-
Phoenix, Arizona
- +118 more
Jun 14, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care)
Completed
- Carcinoma, Hepatocellular
- Doxorubicin 20 mg/m2
- +2 more
-
Canton, Ohio
- +69 more
May 28, 2021
Carcinoma, Hepatocellular Trial in Worldwide (CC-122, Nivolumab)
Completed
- Carcinoma, Hepatocellular
-
Los Angeles, California
- +13 more
Apr 16, 2021
Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))
Completed
- Carcinoma, Hepatocellular
- Refametinib (BAY86-9766)
- Sorafenib (BAY43-9006)
-
Louisville, Kentucky
- +78 more
Apr 6, 2021
Carcinoma, Hepatocellular Trial in Worldwide (LY2157299, Sorafenib, Ramucirumab)
Carcinoma, Hepatocellular Trial in Worldwide (Regorafenib (Stivarga, BAY73-4506), Placebo)
Completed
- Carcinoma, Hepatocellular
- Regorafenib (Stivarga, BAY73-4506)
- Placebo
-
Los Angeles, California
- +146 more
Aug 11, 2020
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- +2 more
-
San Francisco, California
- +126 more
May 16, 2019
Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)
Completed
- Carcinoma, Hepatocellular
- Nexavar (Sorafenib, BAY43-9006)
- Placebo
-
Birmingham, Alabama
- +198 more
Jul 11, 2018
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- Placebo
-
La Jolla, California
- +106 more
Jul 18, 2017
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- Placebo
-
Phoenix, Arizona
- +177 more
Oct 24, 2014